|
[1] CIANCIO A, RIZZETTO M. Chronic hepatitis D at a standstill:Where do we go from here?[J]. Nat Rev Gastroenterol Hep-atol, 2014, 11 (1) :68-71.
|
|
[2] BGUELIN C, MORADPOUR D, SAHLI R, et al. Hepatitis del-ta-associated mortality in HIV/HBV-coinfected patients[J].J Hepatol, 2017, 66 (2) :112.
|
|
[3] ROMEO R, DEL NE, RUMI M, et al. A 28-year study of thecourse of hepatitis Deltainfection:A risk factor for cirrhosis andhepatocellular carcinoma[J]. Gastroenterol Hepatol, 2009, 136 (5) :1629-1638.
|
|
[4] WELLER ML, GARDENER MR, BOGUS ZC, et al. Hepatitisdelta virus detected in salivary glands of Sjgren's syndromepatients and recapitulates a Sjgren's syndrome-like pheno-type in vivo[J]. Pathog Immun, 2016, 1 (1) :12-40.
|
|
[5] FARCI P. Delta hepatitis:An update[J]. J Hepatol, 2003, 39 (1) :212-219.
|
|
[6] FLODGREN E, BENGTSSON S, KNUTSSON M, et al. Recenthigh incidence of fulminant hepatitis in Samara, Russia:Mo-lecular analysis of prevailing hepatitis B and D virus strains[J]. J Clin Microbiol, 2000, 38 (9) :3311-3316.
|
|
[7] RIZZETTO M. Hepatitis D Virus:Introduction and epidemiolo-gy[J]. Cold Spring Harb Perspect Med, 2015, 5:a021576.
|
|
[8] HOLMBERG S, WARD J. Hepatitis delta:Seek and ye shallfind[J]. J Infect Dis, 2010, 202 (6) :822-824.
|
|
[9] WEDEMEYER H. Re-emerging interest in hepatitis delta:New in-sights into the dynamic interplay between HBV and HDV[J]. JHepatol, 2010, 52 (5) :627-629.
|
|
[10] SMEDILE A, LAVARINI C, FARCI P, et al. Epidemiologic pat-terns of infection with the hepatitis B virus-associated delta a-gent in Italy[J]. Am J Epidemiol, 1983, 117 (2) :223-229.
|
|
[11] SHADUR B, MACLACHLAN J, COWIE B. Hepatitis D virus inVictoria 2000-2009[J]. Intern Med J, 2013, 43 (10) :1081-1087.
|
|
[12] GISH RG, YI DH, KANE S, et al. Coinfection with hepatitis Band D:Epidemiology, prevalence and disease in patients inNorthern California[J]. J Gastroenterol Hepatol, 2013, 28 (9) :1521-1525.
|
|
[13] ABBAS Z, JAFRI W, RAZA S. Hepatitis D:Scenario in the A-sia-Pacific region[J]. World J Gastroenterol, 2010, 16 (5) :554-562.
|
|
[14] SHEN L, GU Y, SUN L, et al. Development of a hepatitis del-ta virus antibody assay for study of the prevalence of HDV a-mong individuals infected with hepatitis B virus in China[J]. JMed Virol, 2012, 84 (3) :445-449.
|
|
[15] LIAO B, ZHANG F, LIN S, et al. Epidemiological, clinical andhistological characteristics of HBV/HDV co-infection:A retro-spective cross-sectional study in Guangdong, China[J].PLo S One, 2014, 9 (12) :e115888.
|
|
[16] RIZZETTO M, HOYER B, CANESE MG, et al. Delta agent:Association of delta antigen with hepatitis B surface antigenand RNA in serum of deltainfected chimpanzees[J]. Proc NatlAcad Sci U S A, 1980, 77 (10) :6124-6128.
|
|
[17] BONINO F, HEERMANN KH, RIZZETTO M, et al. Hepatitis deltavirus:Protein composition of delta antigen and its hepatitis B virus-derived envelope[J]. J Virol, 1986, 58 (3) :945-950.
|
|
[18] GUDIMA S, CHANG J, MORALEDA G, et al. Parameters ofhuman hepatitis delta virus genome replication:The quantity, quality, and intracellular distribution of viral proteins and RNA[J]. J Virol, 2002, 76 (8) :3709-3719.
|
|
[19] LEMPP FA, URBAN S. Hepatitis Delta virus:Replication strat-egy and upcoming therapeutic options for a neglected humanpathogen[J]. Viruses, 2017, 9 (7) :172.
|
|
[20] GIERSCH K, ALLWEISS L, VOLZ T, et al. Hepatitis delta co-infection in humanized mice leads to pronounced inductionofinnate immune responses in comparison to HBV mono-infec-tion[J]. J Hepatol, 2015, 63 (2) :346-353.
|
|
[21] CHAO M, HSIEH SY, TAYLOR J. Role of two forms of hepati-tis delta virus antigen:Evidence for a mechanism of selflimitinggenome replication[J]. J Virol, 1990, 64 (3) :5066-5069.
|
|
[22] GLENN JS, WATSON JA, HAVEL CM, et al. Identification of aprenylation site in delta virus large antigen[J]. Science, 1992, 256 (5061) :1331-1333.
|
|
[23] KUO MY, GOLDBERG J, COATES L, et al. Molecular cloningof hepatitis delta virus RNA from an infected woodchuck liver:Sequence, structure, and applications[J]. J Virol, 1988, 62 (6) :1855-1861.
|
|
[24] SUREAU C, NEGRO F. The hepatitis delta virus:Replicationand pathogenesis[J]. J Hepatol, 2016, 64 (1 Suppl) :s102.
|
|
[25] MEI C. RNA recombination in hepatitis delta virus:Implicationsregarding the abilities of mammalian RNA polymerases[J]. Vi-rus Res, 2007, 127 (2) :208-215.
|
|
[26] HUGHES SA, WEDEMEYER H, HRRISON PM. Hepatitis deltavirus[J]. The Lancet, 378 (9785) :73-85.
|
|
[27] TABAKMAN SM, LAU L, ROBINSON JT, et al. Plasmonic substratesfor multiplexed protein microarrays with femtomolar sensitivity andbroad dynamic range[J]. Nat Commun, 2011, 2 (9) :466.
|
|
[28] REGEV A, SCHIFF ER. Clinical features of hepatitis[J]. Se-min Liver Dis, 2012, 32 (3) :228-236.
|
|
[29] TAYLOR JM. Viral hepatitis D[J]. Springer US, 2011, 5:589-595.
|
|
[30] WRANKE A, HEIDRICH B, ERNST S, et al. Anti-HDV IgM asa marker of disease activity in hepatitis delta[J]. PLo S One, 2014, 9 (7) :e101002.
|
|
[31] PASCARELLA S, NEGRO F. Hepatitis D virus:An update[J].Liver Int, 2015, 31 (1) :7-21.
|
|
[32] GRIPPON P, RIBIERE O, CADRANEL JF, et al. Long-termdelta antigenaemia without appearance of delta antibody in twoimmunodeficient patients[J]. Lancet, 1987, 329 (8540) :1031-1031.
|
|
[33] KODANI M, MARTIN A, MIXSON-HAYDEN T, et al. One-step real-time PCR assay for detection and quantitation ofhepatitis D virus RNA[J]. J Virol Methods, 2013, 193 (2) :531-535.
|
|
[34] SMEDILE A, NIRO MG, RIZZETTO M. Detection of serum HDV-RNA by RT-PCR[J]. Methods Mol Med, 2004, 95 (7) :85-93.
|
|
[35] WANG Y, GLENN JS, WINTERS MA, et al. A new dual-targetingreal-time RT-PCR assay for hepatitis D virus RNA detection[J].Diagn Microbiol Infect Dis, 2018, 92 (2) :112-117.
|
|
[36] YAMASHIRO T, NAGAYAMA K, ENOMOTO N, et al. Quantifica-tion of the levelof hepatitis delta virus RNA in serum, by real-timepolymerase chain reaction, and its possible correlation with theclinical stage of liver disease[J]. J Infect Dis, 2004, 189 (7) :1151-1157.
|
|
[37] ROMEO R, FOGLIENI B, CASAZZA G, et al. High serum levels ofHDV RNA are predictors of cirrhosis and liver cancer in patientswith chronic hepatitis delta[J]. PLo S One, 2014, 9 (3) :e92062.
|
|
[38] BRICHLER S, LE GAL F, BUTT A, et al. Commercial real-timereverse transcriptase PCR assays can underestimate or fail toquantify hepatitis delta virus viremia[J]. Clin Gastroenterol Hepa-tol, 2013, 11 (6) :734-740.
|
|
[39] BATTEGAY M, SIMPSON LH, HOOFNAGLE JH, et al. Eliminationof hepatitis delta virus infection after loss of hepatitis B surface an-tigen in patients with chronic delta hepatitis[J]. J Med Virol, 1994, 44 (4) :389-392.
|
|
[40] LUTTERKORT GL, WRANKE A, HENGST J, et al. Viral domi-nance patterns in chronic hepatitis delta determine early responseto interferon alpha therapy[J]. J Viral Hepat, 2018, 25 (11) :1384-1394.
|
|
[41] URBAN S. Liver capsule:Entry and entry inhibition of hepatitis Bvirus and hepatitis delta virus into hepatocytes[J]. Hepatology, 2016, 63 (2) :633.
|
|
[42] TAVANEZ JP, CUNHA C, SILVA MC, et al. Hepatitis delta virus ri-bonucleoproteins shuttle between the nucleus and the cytoplasm[J]. RNA, 2002, 8 (5) :637-646.
|
|
[43] SHELDON J, RAMOS B, TORO C, et al. Does treatment of hepa-titis B virus infection reduce hepatitis delta virus replication in HIV-HBV-HDV coinfected patients?[J]. Antiviral Ther, 2008, 13 (1) :97-102.
|
|
[44] REIJNDERS JG, RICKBORST V, SONNEVELD MJ, et al. Kineticsof hepatitis B surface antigen differ between treatment withpeginterferon with and entecavir[J]. J Hepatol, 2011, 54 (3) :449-454.
|
|
[45] HEIDRICH B, YURDAYD C, KABAAM G, et al. Late HDV RNArelapse after peginterferon alpha-based therapy of chronic hepa-titis delta[J]. Hepatology, 2014, 60 (1) :87-97.
|
|
[46] YURDAYDIN C, BOZKAYA H, ONDER FO, et al. Treatment ofchronic delta hepatitis with lamivudine vs. lamivudine+interferonvs. interferon[J]. J Viral Hepat, 2008, 15 (4) :314-321.
|
|
[47] LANFORD RE, GUERRA B, CHAVEZ D, et al. GS-9620, an oralagonist of Toll-like receptor-7, induces prolonged suppressionof hepatitis B virus in chronically infected chimpanzees[J]. Gas-troenterology, 2013, 144 (7) :1508-1517.
|
|
[48] ELAZAR M, GLENN JS. Emerging concepts for the treatment ofhepatitis delta[J]. Curr Opin Virol, 2017, 24:55-59.
|
|
[49] HUANG J, PANG XQ, XIE DY. Role of DNA recognition receptorsin pathogenic mechanism of hepatitisB[J]. J Clin Hepatol, 2017, 33 (9) :1794-1797. (in Chinese) 黄劲, 庞秀青, 谢冬英. DNA识别受体在乙型肝炎发病机制中的作用[J].临床肝胆病杂志, 2017, 33 (9) :1794-1797.
|
|
[50] WINER BY, SHIRVANI-DASTGERDI E, BRAM Y, et al. Preclinicalassessment of antiviral combination therapy in a genetically hu-manized mouse model for hepatitis delta virus infection[J]. SciTransl Med, 2018, 10 (447) :eaap9328.
|
|
[51] YURDAYDIN C, IDILMAN R, KALKAN R, et al. A phase 2 dose-optimization study of Lonafarnib with Ritonavir for the treatment ofchronic delta hepatitis-end of treatment results from the LOWRHDV-2 study[J]. J Hepatol, 2017, 66 (1) :33-34.
|
|
[52] BAZINET M, PANTEA V, CEBOTARESCU V, et al. Update on thesafety and efficacy of REP 2139 monotherapy and subsequentcombination therapy with pegylated interferon alpha-2a in Cauca-sian patients with chronic HBV/HDV coinfection[J]. J Hepatol, 2016, 64 (2) :s584-s585.
|
DownLoad: